Tejas Savant
Stock Analyst at Morgan Stanley
(2.26)
# 2,663
Out of 4,910 analysts
227
Total ratings
41.09%
Success rate
-2.89%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $9 → $7 | $3.37 | +107.72% | 9 | May 28, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $26 → $18 | $13.62 | +32.16% | 14 | May 19, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $136 → $100 | $104.61 | -4.41% | 8 | May 12, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $60 → $65 | $64.86 | +0.22% | 3 | May 9, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $77 → $65 | $65.92 | -1.40% | 9 | May 5, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $7.81 | -10.37% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $10.87 | -17.20% | 12 | May 5, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $17 → $10 | $6.61 | +51.29% | 13 | May 1, 2025 | |
| AVTR Avantor | Downgrades: Equal-Weight | $25 → $15 | $13.60 | +10.29% | 19 | Apr 28, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $2.63 | +90.48% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $40.88 | -51.08% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $185 | $137.82 | +34.23% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $194.24 | +28.71% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $647 → $678 | $466.71 | +45.27% | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $25.41 | -9.48% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $24.21 | +15.65% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $4.74 | +343.04% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.69 | +18.34% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $14.14 | +182.89% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.74 | +709.72% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.61 | +177.01% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $4.03 | -31.76% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $6.76 | -26.04% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.12 | +371.70% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $45.45 | +60.62% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $167.95 | +48.85% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.42 | +1,077.02% | 5 | May 12, 2022 |
Cytek Biosciences
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $3.37
Upside: +107.72%
10x Genomics
May 19, 2025
Maintains: Overweight
Price Target: $26 → $18
Current: $13.62
Upside: +32.16%
Illumina
May 12, 2025
Maintains: Equal-Weight
Price Target: $136 → $100
Current: $104.61
Upside: -4.41%
Tempus AI
May 9, 2025
Maintains: Overweight
Price Target: $60 → $65
Current: $64.86
Upside: +0.22%
Hologic
May 5, 2025
Maintains: Equal-Weight
Price Target: $77 → $65
Current: $65.92
Upside: -1.40%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $7.81
Upside: -10.37%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $10.87
Upside: -17.20%
NeoGenomics
May 1, 2025
Maintains: Equal-Weight
Price Target: $17 → $10
Current: $6.61
Upside: +51.29%
Avantor
Apr 28, 2025
Downgrades: Equal-Weight
Price Target: $25 → $15
Current: $13.60
Upside: +10.29%
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.63
Upside: +90.48%
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $40.88
Upside: -51.08%
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $137.82
Upside: +34.23%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $194.24
Upside: +28.71%
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $466.71
Upside: +45.27%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $25.41
Upside: -9.48%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $24.21
Upside: +15.65%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $4.74
Upside: +343.04%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.69
Upside: +18.34%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $14.14
Upside: +182.89%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.74
Upside: +709.72%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.61
Upside: +177.01%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $4.03
Upside: -31.76%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $6.76
Upside: -26.04%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.12
Upside: +371.70%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $45.45
Upside: +60.62%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $167.95
Upside: +48.85%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.42
Upside: +1,077.02%